114. Long term survival following a randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases

2014 ◽  
Vol 40 (11) ◽  
pp. S53
Author(s):  
J. Xu ◽  
L.C. Ye ◽  
T.S. Liu ◽  
L. Ren ◽  
Y. Wei ◽  
...  
Author(s):  
Amir R. Dehdashti ◽  
Sunjay Sharma ◽  
Normand Laperriere ◽  
Mark Bernstein

Background:Very long term survival after diagnosis of malignant glioma has been described in individual case reports. Survival of more than 10 years is extremely rare, especially when identified in 3 out of 71 patients assigned to one arm of a randomized controlled trial.Patients:Three patients survived 11, 16, and 18 years following the diagnosis of glioblastoma and treatment with surgery, conventional fractionated radiation, and high-activity iodine-125 boost brachytherapy as part of a randomized controlled trial.Conclusion:Despite this apparent cause and effect relationship, statistical analysis shows no relationship between these cures and treatment with brachytherapy. Cure of glioblastoma remains rare.


Sign in / Sign up

Export Citation Format

Share Document